The Effect of Drug Loading and Multiple Administration on the Protein Corona Formation and Brain Delivery Property of PEG-PLA Nanoparticles

Overview

Journal Acta Pharm Sin B

Publisher Elsevier

Specialty Pharmacology

Date 2022 Jul 18

PMID 35847504

Authors

Yuyun Tang

Jinchao Gao

Tao Wang

Qian Zhang

Antian Wang

Meng Huang

Renhe Yu

Hongzhuan Chen

Xiaoling Gao

Affiliations

Soon will be listed here.

Abstract

The presence of protein corona on the surface of nanoparticles modulates their physiological interactions such as cellular association and targeting property. It has been shown that -mangostin (M)-loaded poly(ethylene glycol)-poly(l-lactide) (PEG-PLA) nanoparticles (NP-M) specifically increased low density lipoprotein receptor (LDLR) expression in microglia and improved clearance of amyloid beta (A) after multiple administration. However, how do the nanoparticles cross the blood‒brain barrier and access microglia remain unknown. Here, we studied the brain delivery property of PEG-PLA nanoparticles under different conditions, finding that the nanoparticles exhibited higher brain transport efficiency and microglia uptake efficiency after M loading and multiple administration. To reveal the mechanism, we performed proteomic analysis to characterize the composition of protein corona formed under various conditions, finding that both drug loading and multiple dosing affect the composition of protein corona and subsequently influence the cellular uptake of nanoparticles in b.End3 and BV-2 cells. Complement proteins, immunoglobulins, RAB5A and CD36 were found to be enriched in the corona and associated with the process of nanoparticles uptake. Collectively, we bring a mechanistic understanding about the modulator role of protein corona on targeted drug delivery, and provide theoretical basis for engineering brain or microglia-specific targeted delivery system.

Citing Articles

Recent advances in the bench-to-bedside translation of cancer nanomedicines.

Liu Y, Zhang Y, Li H, Hu T Acta Pharm Sin B. 2025; 15(1):97-122.

PMID: 40041906 PMC: 11873642. DOI: 10.1016/j.apsb.2024.12.007.

Advanced Nanopharmaceutical Intervention for the Reduction of Inflammatory Responses and the Enhancement of Behavioral Outcomes in APP/PS1 Transgenic Mouse Models.

Li J, Huang D, Liao W, Wang Y, Liu Y, Luan P Pharmaceutics. 2025; 17(2).

PMID: 40006544 PMC: 11859494. DOI: 10.3390/pharmaceutics17020177.

Nanoscale drug formulations for the treatment of Alzheimer's disease progression.

Liu L, He H, Du B, He Y RSC Adv. 2025; 15(6):4031-4078.

PMID: 39926227 PMC: 11803502. DOI: 10.1039/d4ra08128e.

Bridging immune-neurovascular crosstalk via the immunomodulatory microspheres for promoting neural repair.

Xu T, Gan L, Chen W, Zheng D, Li H, Deng S Bioact Mater. 2024; 44:558-571.

PMID: 39584066 PMC: 11583666. DOI: 10.1016/j.bioactmat.2024.10.031.

Overcoming Barriers in Glioblastoma-Advances in Drug Delivery Strategies.

Ter Linden E, Abels E, van Solinge T, Neefjes J, Broekman M Cells. 2024; 13(12.

PMID: 38920629 PMC: 11201826. DOI: 10.3390/cells13120998.

References

Tavano R, Gabrielli L, Lubian E, Fedeli C, Visentin S, Polverino de Laureto P . C1q-Mediated Complement Activation and C3 Opsonization Trigger Recognition of Stealth Poly(2-methyl-2-oxazoline)-Coated Silica Nanoparticles by Human Phagocytes. ACS Nano. 2018; 12(6):5834-5847. PMC: 6251765. DOI: 10.1021/acsnano.8b01806. View

Merle N, Church S, Fremeaux-Bacchi V, Roumenina L . Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol. 2015; 6:262. PMC: 4451739. DOI: 10.3389/fimmu.2015.00262. View

Mahmoudi M, Lynch I, Ejtehadi M, Monopoli M, Bombelli F, Laurent S . Protein-nanoparticle interactions: opportunities and challenges. Chem Rev. 2011; 111(9):5610-37. DOI: 10.1021/cr100440g. View

Simon J, Muller L, Kokkinopoulou M, Lieberwirth I, Morsbach S, Landfester K . Exploiting the biomolecular corona: pre-coating of nanoparticles enables controlled cellular interactions. Nanoscale. 2018; 10(22):10731-10739. DOI: 10.1039/c8nr03331e. View

Dobri A, Dudau M, Enciu A, Hinescu M . CD36 in Alzheimer's Disease: An Overview of Molecular Mechanisms and Therapeutic Targeting. Neuroscience. 2020; 453:301-311. DOI: 10.1016/j.neuroscience.2020.11.003. View

Monopoli M, Aberg C, Salvati A, Dawson K . Biomolecular coronas provide the biological identity of nanosized materials. Nat Nanotechnol. 2012; 7(12):779-86. DOI: 10.1038/nnano.2012.207. View

Yu L, Xu M, Xu W, Xiao W, Jiang X, Wang L . Enhanced Cancer-targeted Drug Delivery Using Precoated Nanoparticles. Nano Lett. 2020; 20(12):8903-8911. DOI: 10.1021/acs.nanolett.0c03982. View

Al-Ahmady Z, Hadjidemetriou M, Gubbins J, Kostarelos K . Formation of protein corona in vivo affects drug release from temperature-sensitive liposomes. J Control Release. 2018; 276:157-167. DOI: 10.1016/j.jconrel.2018.02.038. View

Kinchen J, Doukoumetzidis K, Almendinger J, Stergiou L, Tosello-Trampont A, Sifri C . A pathway for phagosome maturation during engulfment of apoptotic cells. Nat Cell Biol. 2008; 10(5):556-66. PMC: 2851549. DOI: 10.1038/ncb1718. View

10.

Ishida T, Harada M, Wang X, Ichihara M, Irimura K, Kiwada H . Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J Control Release. 2005; 105(3):305-17. DOI: 10.1016/j.jconrel.2005.04.003. View

11.

Yang Q, Lai S . Anti-PEG immunity: emergence, characteristics, and unaddressed questions. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2015; 7(5):655-77. PMC: 4515207. DOI: 10.1002/wnan.1339. View

12.

Hadjidemetriou M, Al-Ahmady Z, Buggio M, Swift J, Kostarelos K . A novel scavenging tool for cancer biomarker discovery based on the blood-circulating nanoparticle protein corona. Biomaterials. 2018; 188:118-129. DOI: 10.1016/j.biomaterials.2018.10.011. View

13.

Pacheco P, White D, Sulchek T . Effects of microparticle size and Fc density on macrophage phagocytosis. PLoS One. 2013; 8(4):e60989. PMC: 3632606. DOI: 10.1371/journal.pone.0060989. View

14.

Furtado D, Bjornmalm M, Ayton S, Bush A, Kempe K, Caruso F . Overcoming the Blood-Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases. Adv Mater. 2018; 30(46):e1801362. DOI: 10.1002/adma.201801362. View

15.

Tenzer S, Docter D, Kuharev J, Musyanovych A, Fetz V, Hecht R . Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. Nat Nanotechnol. 2013; 8(10):772-81. DOI: 10.1038/nnano.2013.181. View

16.

Kim T, Kim D, Chung J, Shin S, Kim S, Heo D . Phase I and pharmacokinetic study of Genexol-PM, a cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies. Clin Cancer Res. 2004; 10(11):3708-16. DOI: 10.1158/1078-0432.CCR-03-0655. View

17.

Kim H, Andrieux K, Delomenie C, Chacun H, Appel M, Desmaele D . Analysis of plasma protein adsorption onto PEGylated nanoparticles by complementary methods: 2-DE, CE and Protein Lab-on-chip system. Electrophoresis. 2007; 28(13):2252-61. DOI: 10.1002/elps.200600694. View

18.

Wu J, Zhao J, Zhang B, Qian Y, Gao H, Yu Y . Polyethylene glycol-polylactic acid nanoparticles modified with cysteine-arginine-glutamic acid-lysine-alanine fibrin-homing peptide for glioblastoma therapy by enhanced retention effect. Int J Nanomedicine. 2014; 9:5261-71. PMC: 4235507. DOI: 10.2147/IJN.S72649. View

19.

Lundqvist M, Stigler J, Elia G, Lynch I, Cedervall T, Dawson K . Nanoparticle size and surface properties determine the protein corona with possible implications for biological impacts. Proc Natl Acad Sci U S A. 2008; 105(38):14265-70. PMC: 2567179. DOI: 10.1073/pnas.0805135105. View

20.

Chen D, Ganesh S, Wang W, Amiji M . Plasma protein adsorption and biological identity of systemically administered nanoparticles. Nanomedicine (Lond). 2017; 12(17):2113-2135. DOI: 10.2217/nnm-2017-0178. View